Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 2:03 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 409–432 of 33,121 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo Clear all
Completed Phase 2 Interventional Results available

Effectiveness of Arginine as a Treatment for Sickle Cell Anemia

NCT00513617
View directory record Official record
Conditions
Anemia, Sickle Cell
Interventions
Arginine, Placebo
Drug
Lead sponsor
UCSF Benioff Children's Hospital Oakland
Other
Eligibility
5 Years and older
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
17
States / cities
Oakland, California • San Francisco, California • Denver, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2017 · Synced Oct 31, 2026, 2:03 PM EDT
Not listed Phase 2 Interventional

Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple Sclerosis

NCT05054140
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
IMU-838, Placebo matching IMU-838
Drug
Lead sponsor
Immunic AG
Industry
Eligibility
18 Years to 65 Years
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
8
States / cities
Coral Springs, Florida • Naples, Florida • Ormond Beach, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2024 · Synced Oct 31, 2026, 2:03 PM EDT
Terminated Phase 2 Interventional

A Study of the Activity of Eculizumab for Prevention of Delayed Graft Function In Deceased Donor Kidney Transplant

NCT01403389
View directory record Official record
Conditions
Delayed Function of Renal Transplant
Interventions
Eculizumab, Placebo
Drug
Lead sponsor
Schroppel, Bernd, M.D.
Individual
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 6, 2019 · Synced Oct 31, 2026, 2:03 PM EDT
Completed Phase 2 Interventional Results available

A Study of Experimental Medication BMS-986263 in Adults With Advanced Hepatic Fibrosis After Cure of Hepatitis C

NCT03420768
View directory record Official record
Conditions
Hepatic Cirrhosis, Liver Fibrosis
Interventions
BMS-986263, Placebo
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
21 Years to 75 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 4, 2022 · Synced Oct 31, 2026, 2:03 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Trial to Assess the Pharmacokinetics and Pharmacodynamics of a Novel Synbiotic Oral Supplement for Vaginal Health

NCT07435350
View directory record Official record
Conditions
Vaginal Health
Interventions
Vaginal Health Placebo Control, Vaginal Health Active VV-01
Dietary Supplement
Lead sponsor
Radicle Science
Industry
Eligibility
21 Years to 60 Years · Female only
Enrollment
220 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Del Mar, California
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 31, 2026, 2:03 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of LY3009104(Baricitinib) for Healthy Subjects

NCT01247350
View directory record Official record
Conditions
Healthy Volunteer
Interventions
LY3009104, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
20 Years to 65 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Apr 13, 2018 · Synced Oct 31, 2026, 2:03 PM EDT
Terminated Phase 2 Interventional Results available

A Study of LY3202626 on Disease Progression in Participants With Mild Alzheimer's Disease Dementia

NCT02791191
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
LY3202626, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
55 Years to 85 Years
Enrollment
316 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
49
States / cities
Irvine, California • Sacramento, California • San Diego, California + 40 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2021 · Synced Oct 31, 2026, 2:03 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Effects of Fish Oil and Red Wine on Oxidative Stress Biomarkers

NCT00682318
View directory record Official record
Conditions
Healthy
Interventions
Fish Oil, Safflower Oil, Ethanol, Omega-3 polyunsaturated fatty acids, Omega-6 polyunsaturated fatty acid
Drug · Dietary Supplement
Lead sponsor
Carsten Skarke, MD
Other
Eligibility
21 Years to 60 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2029
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Oct 31, 2026, 2:03 PM EDT
Completed Phase 1 Interventional

Safety and Immune Response Assessment Study of Killed-whole HIV-1 Vaccine (SAV001-H) in Chronic HIV-1 Infected Patients

NCT01546818
View directory record Official record
Conditions
HIV Infections
Interventions
SAV001-H
Biological
Lead sponsor
Sumagen
Industry
Eligibility
18 Years to 50 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 9, 2013 · Synced Oct 31, 2026, 2:03 PM EDT
Completed Phase 1 Interventional

Single-Dose Study Of PF-04603629 In Type 2 Diabetic Subjects

NCT00638313
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Placebo, PF-04603629
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
2
States / cities
Phoenix, Arizona • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 31, 2009 · Synced Oct 31, 2026, 2:03 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Exemestane Plus Dasatinib Versus Placebo for Advanced ER+ Breast Cancer

NCT00767520
View directory record Official record
Conditions
Breast Cancer
Interventions
Exemestane + Dasatinib, Exemestane + Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
4
States / cities
Fountain Valley, California • Riverside, California • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2013 · Synced Oct 31, 2026, 2:03 PM EDT
Completed Phase 2 Interventional

A Study of the Safety and Efficacy of ONO-4641 in Patients With Relapsing-Remitting Multiple Sclerosis

NCT01081782
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
ONO-4641, ONO-4641 placebo
Drug
Lead sponsor
Ono Pharma USA Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
407 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
23
States / cities
Tucson, Arizona • Aurora, Colorado • Fort Collins, Colorado + 19 more
Source: ClinicalTrials.gov public record
Updated Dec 25, 2013 · Synced Oct 31, 2026, 2:03 PM EDT
Completed Phase 3 Interventional

A Study on The Potential of Aleglitazar to Reduce Cardiovascular Risk in Patients With Stable Cardiovascular Disease and Glucose Abnormalities

NCT01715818
View directory record Official record
Conditions
Cardiovascular Disease, Diabetes Mellitus Type 2
Interventions
Placebo, aleglitazar
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
40 Years and older
Enrollment
1,999 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
143
States / cities
Muscle Shoals, Alabama • Gilbert, Arizona • Phoenix, Arizona + 126 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 31, 2026, 2:03 PM EDT
Not yet recruiting Phase 1 Interventional

Anakinra Rescue Treatment for Moderate Asthma Attacks (ARTMA)

NCT07600190
View directory record Official record
Conditions
Asthma (Diagnosis), Persistent Asthma, Moderate Asthma Exacerbation
Interventions
Anakinra 100 Mg/0.67 Ml Inj Syringe, Saline Placebo/0.67 Ml Inj Syringe
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Oct 31, 2026, 2:03 PM EDT
Completed Phase 1 Interventional

An Initial Study of AZD7325 in Adults With Fragile X Syndrome

NCT03140813
View directory record Official record
Conditions
Fragile X Syndrome
Interventions
AZD7325 (High-Dose), AZD7325 (Low-Dose), Placebo oral capsule
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
18 Years to 50 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 8, 2021 · Synced Oct 31, 2026, 2:03 PM EDT
Completed Phase 2 Interventional Results available

Phase 2a Study of Efficacy and Safety of OpSCF in Moderate to Severe AD (Atopic Dermatitis)

NCT06101823
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
OpSCF, Placebo
Biological
Lead sponsor
Insmed Incorporated
Industry
Eligibility
18 Years to 75 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
18
States / cities
Birmingham, Alabama • Fountain Valley, California • Inglewood, California + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 31, 2026, 2:03 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of SJP-0035 Ophthalmic Solution in Patients With Moderate to Severe Corneal Epithelial Disorders

NCT02929823
View directory record Official record
Conditions
Corneal Epithelial Disorders
Interventions
High Dose SJP-0035 Ophthalmic Solution, Low Dose SJP-0035 Ophthalmic Solution, Vehicle of SJP-0035 Ophthalmic solution
Drug
Lead sponsor
Senju Pharmaceutical Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
19
States / cities
Little Rock, Arkansas • Glendora, California • Lancaster, California + 16 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2021 · Synced Oct 31, 2026, 2:03 PM EDT
Completed Phase 1 Interventional Results available

A Double-Blind, Multiple Ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of DX-2930 in Hereditary Angioedema Participants

NCT02093923
View directory record Official record
Conditions
Hereditary Angioedema (HAE)
Interventions
DX-2930, Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
12
States / cities
San Diego, California • Walnut Creek, California • Tampa, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated May 27, 2021 · Synced Oct 31, 2026, 2:03 PM EDT
Completed Phase 2 Interventional

Rifamycin in Minimal Hepatic Encephalopathy

NCT04082780
View directory record Official record
Conditions
Hepatic Encephalopathy, Cirrhosis, Liver
Interventions
Rifamycin SV MMX, Placebo
Drug · Other
Lead sponsor
Hunter Holmes Mcguire Veteran Affairs Medical Center
Federal
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Oct 31, 2026, 2:03 PM EDT
Completed Phase 2 Interventional

A Study Of The Effectiveness Of Wafermine Alone And In Combination With Opioids In Subjects Undergoing Bunionectomy

NCT02541396
View directory record Official record
Conditions
Acute Pain
Interventions
Wafermine, Oxycodone, Placebo
Drug
Lead sponsor
iX Biopharma Ltd.
Other
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Feb 23, 2016 · Synced Oct 31, 2026, 2:03 PM EDT
Recruiting Phase 3 Interventional

Evaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral Neuropathy

NCT06628908
View directory record Official record
Conditions
Diabetic Peripheral Neuropathic Pain
Interventions
Suzetrigine, Placebo (matched to SUZ), Pregabalin, Placebo (matched to Pregabalin)
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 80 Years
Enrollment
1,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
76
States / cities
Anniston, Alabama • Birmingham, Alabama • Daphne, Alabama + 68 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 31, 2026, 2:03 PM EDT
Completed Phase 4 Interventional Results available

A Study Evaluating the Gastrointestinal (GI) Safety and Tolerability of Aliskiren Compared to Ramipril in Essential Hypertension

NCT00631917
View directory record Official record
Conditions
Hypertension
Interventions
Aliskiren, Ramipril, Placebo to Ramipril, Placebo to Aliskiren
Drug · Other
Lead sponsor
Novartis
Industry
Eligibility
50 Years and older
Enrollment
774 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 12, 2011 · Synced Oct 31, 2026, 2:03 PM EDT
Completed Phase 2 Interventional

EC-18 for Oral Mucositis in Patients With Concomitant Chemoirradiation

NCT03200340
View directory record Official record
Conditions
Stomatitis
Interventions
EC-18, Placebo
Drug
Lead sponsor
Enzychem Lifesciences Corporation
Industry
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
20
States / cities
Long Beach, California • Los Angeles, California • Miami, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2023 · Synced Oct 31, 2026, 2:03 PM EDT
Completed Phase 3 Interventional Results available

A Study to Investigate Mepolizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis

NCT02020889
View directory record Official record
Conditions
Churg-Strauss Syndrome
Interventions
Mepolizumab, Placebo
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
8
States / cities
Denver, Colorado • Bethesda, Maryland • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2018 · Synced Oct 31, 2026, 2:03 PM EDT